Volume 10, Number 4, September-October 2003

Phosphodiesterase type 5 (PDE5) inhibitors: looking beyond erectile dysfunction
A round-table meeting to discuss the management of erectile dysfunction was held in London in June. Participants heard about the cardiac safety and cardiac potential of PDE5 inhibitors, and agreed a number of points about the clinical benefits and use of these agents. This supplement contains a report of the meeting.

Br J Cardiol 2003;10:S1-S8.

View full PDF article (open in new window)
Email this article